Edit

Novalis Biotech

https://noval.is
Last activity: 23.03.2025
Probably Closed
Invests in categories: HealthTechMedTechPlatformResearchTechnologyDataDiagnosticsArtificial IntelligencePersonalIT
News
44
Portfolio
17
Persons
9
Mentions
16
Location: Belgium, East Flanders, Ghent
Employees: 1-10
Investment Type: Venture Capital
Investment Stage: Pre-Seed; Seed; Series A

Portfolio 17

DateNameWebsiteTotal RaisedLocation
20.03.2024301 Moved ...rheumafinder.ai--
09.12.2023301 Moved ...myneotx.com--
07.02.2023Rarity Bio...raritybioscience.com$10.23MSweden, Up...
31.01.2023C-mo Medic...c-mo.solutions$9.33M-
24.05.2022Alithea Ge...alitheagenomics.com$4.22MSwitzerlan...
07.06.2021Rheavitarheavita.com$3.05M-
09.02.2021Graphealgrapheal.com$2.3MFrance, Au...
-Cergentiscergentis.com-Argentina,...
-Trince Biotrincebio.com$4.53MBelgium, E...
-Epify BVepify.nl$564.63KNetherland...
Show more

Persons 9

DateFirst NameLast NameTitleLinkedInLocation
-CedricBogaert-linkedin.c...-
-JanVan den Be...-linkedin.c...-
-KathleenVan den Be...-linkedin.c...-
-WimVan Crieki...-linkedin.c...-
-JaroslavBelotserko...-linkedin.c...-
-KjellMortier-linkedin.c...-
-LiesbethCeelen--
-MichaelHengartner--
-BartRossel--

News 44

DateTitleDescription
22.03.2025BioLizard Awarded Grant from VLAIO to Advance AI-Powered Biomedical Solution for Accelerated Drug Development March 6th 2025, Ghent BE, BioLizard, a leading bioinformatics, data analytics and data engineering consulting company driving digital transformation in the life sciences industry, has...
22.03.2025Beckman Coulter Life Sciences and Rarity Bioscience AB sign Partnership March 5th, 2025, Indianapolis, US. Beckman Coulter Life Sciences, a global leader in laboratory automation and innovation, in partnership with Rarity Bioscience AB offers a...
30.11.2024RheaVita Announces Strategic Partnership With IMA Life Ghent, Belgium, 18 November 2024, RheaVita Announces Strategic Partnership With IMA Life, Part of the IMA Group, to Drive Further Technological Development and Commercial Growth.
08.08.2024Anacura acquires OHMX.bio, a Novalis fund I portfolio company, and extends its service with multi-omics for drug discovery and diagnostics July 4th, 2024. Ghent, Belgium Anacura acquires OHMX.bio, a Novalis fund I portfolio company, and extends its service with multi-omics for drug discovery and diagnostics
08.08.2024Novalis II portfolio company Trince awarded winner of Nature Spinoff Prize 2024 July 11th 2024, Ghent (BE). Novalis II portfolio company Trince is awarded the Spinoff Prize from the prestigious Nature Magazine
08.08.2024Rarity Bioscience announces the successful closure of a €6.5 million funding round June, 18th 2024, Uppsala, Sweden. Rarity Bioscience, a pioneering molecular biotech company, is pleased to announce the successful closure of a €6.5 million funding round....
14.03.2024Alithea Genomics Closes CHF 2.8 Million in Seed Financing Extension Led by Novalis Biotech Alithea Genomics, an emerging leader in the field of large-scale RNA sequencing and transcriptomics, announced today the closing of a CHF 2.8 million ($3.2 million)...
02.03.2024Altavo concludes Series A for the development of its Artificial Voice Altavo, a startup in AI-based voice rehabilitation founded in 2021, successfully closed its Series A financing round on February 1, 2024.
02.03.2024RheumaFinder Announces Investment to revolutionize care for patients with rheumatic disease Ghent, Belgium, February 2024 – RheumaFinder is excited to announce an investment from Belgium's Novalis Biotech Acceleration Fund. This investment, executed as a seed-participation in...
27.11.2023myNEO evolves into myNEO Therapeutics to reflect its new strategy to develop off-the-shelf cancer vaccine immunotherapeutics.
Show more

Mentions in press and media 16

DateTitleDescription
17.03.2024Alithea Genomics Revolutionizes RNA Sequencing with CHF 2.8 Million Seed Financing ExtensionAlithea Genomics, a game-changer in RNA sequencing, secures CHF 2.8 million in seed financing extension led by Novalis Biotech. Their innovative BRB-seq and DRUG-seq technologies streamline RNA sample preparation, slashing costs and time. B...
14.03.2024Alithea Genomics Closes CHF 2.8 Million in Seed Financing Extension Led by Novalis Biotech Alithea Genomics, an emerging leader in the field of large-scale RNA sequencing and transcriptomics, announced today the closing of a CHF 2.8 million ($3.2 million)...
14.03.2024Alithea Genomics secures CHF 2.8 million in Seed financing extension led by Novalis BiotechAlithea commercializes multiplexed library preparation solutions for RNA sequencing, most notably BRB-seq and DRUG-seq. These technologies prepare hundreds of RNA samples for sequencing in a single tube and, in the case of DRUG-seq, without...
14.03.2024Alithea Genomics eyes the US market after closing seed round Based in Lausanne, Alithea Genomics is an emerging company in the field of large-scale RNA sequencing and transcriptomics. The company commercializes massively multiplexed library preparation solutions for RNA sequencing, with two products...
14.03.2024Alithea Genomics secures CHF 2.8 million in Seed financing extension led by Novalis BiotechAlithea Genomics secures CHF 2.8 million in Seed financing extension led by Novalis Biotech 14.03.2024 08:01, Rita Longobardi linkedIn facebook twitter instagram youtube --> The funding will support the commercialization and manufacturin...
08.09.2022France-based Carroucell raises EUR 1.5 million in Series AGrenoble, a France-based microcarrier supplier for cell culture in the bioreactor, Carroucell raised EUR 1.5 million. The Series A funding took place on September 7, 2022. Novalis Biotech Acceleration fund led the financing for the company....
10.06.2022Alithea Genomics Raises CHF 1 Million in Seed Financing Round Led by Novalis Biotech
24.05.2022Alithea Genomics completes seed round
01.07.2021Novalis Biotech closes second fund on €25MEarly-stage investor Novalis Biotech has closed its second Biotech Acceleration Fund on €25 million. The vehicle will be used to back startups and scale-up companies reshaping healthcare with technologies such as bioinformatics and genomics...
02.06.2021RheaVita : Closes EUR 2.5 million Series A Financing Co-Led by Novalis Biotech Acceleration and PMVRheaVita, a company pioneering continuous freeze-drying technology for biopharmaceutical products, announced today that the company has closed a EUR 2.5 million Series A Financing. The round was co-led by Novalis Biotech Acceleration and Pa...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In